In addition to cancer, genome-wide association studies have repeatedly and confidently identified links between the genomic region containing ANRIL and risk of developing cardiometabolic disease, including type 2 diabetes and manifestations of atherosclerosis such as CAD and stroke (10, 62). This evidence concerns the gene CDKN2B-AS1 and stroke disorder.